Kidney fibrosis preclinical models
Renal fibrosis is a hallmark of chronic kidney disease (CKD) and a key contributor to progressive renal dysfunction. It is characterized by excessive extracellular matrix deposition, leading to scarring, loss of kidney function, and ultimately, end-stage renal disease. Despite its critical role in CKD, effective therapeutic interventions remain limited, making preclinical research essential for developing targeted treatments.
Discover our validated kidney fibrosis models to accelerate and de-risk the preclinical development of antifibrotic therapies.
In vitro kidney fibrosis assay
We offer high-throughput and physiologically relevant cell-based assays to study kidney fibrosis mechanisms and drug responses:
- Fibroblasts, podocytes, and tubular epithelial cells.
- TGF-β Induced Fibrosis Assays – Evaluate drug efficacy in modulating pro-fibrotic pathways.
- Co-Culture Systems – Mimicking the renal microenvironment for better predictability.
- High-Content Imaging & Biomarker Analysis – Automated quantification of fibrosis-related markers
In vivo kidney fibrosis models
Our validated in vivo kidney fibrosis models ensure high translational value for preclinical drug assessment:
- UUO (Unilateral Ureteral Obstruction) Model – Rapid surgical model for screening anti-fibrotic molecules efficacy.
- Unilateral Ischemia reperfusion Model – Clinically relevant AKI-to-CKD transition model
- Adenine Diet-Induced CKD Model – Chronic kidney disease model reflecting human pathology.
- Biomarker & Histopathological Evaluations – Comprehensive assessment of fibrotic progression and drug impact.